Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Autism Spectrum Disorder, Behavior Problem
Interventions: Crisis Prevention Arm, Control; Other
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 3 Years to 17 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 40
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Depemokimab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 56
States / cities: Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 48 more

Conditions: Erectile Dysfunction
Interventions: LY2452473, Tadalafil, LY900010; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pain
Interventions: placebo, ibuprofen Formulation 1, ibuprofen Formulation 2; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
Interventions: Dordaviprone (ONC201); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 8
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Diffuse Intrinsic Pontine Glioma
Interventions: Panobinostat Nanoparticle Formulation MTX110, Convection-Enhanced Delivery (CED); Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 2 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, FFB, PBS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • New York, New York + 3 more

Conditions: Chronic Hand Eczema (CHE)
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • Huntington Beach, California • Westminster, California + 8 more

Conditions: Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Abraxane, Alimta; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Alzheimer's Disease
Interventions: Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 23
States / cities: Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more

Conditions: Sunscreening Agent
Interventions: Coppertone (BAY987516); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Sunscreening Agent
Interventions: Coppertone (BAY 987517); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Acromegaly
Interventions: Debio 4126, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Anesthesia, Local
Interventions: AG-920, Placebo; Drug
Lead sponsor: American Genomics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Arthritis, Psoriatic
Interventions: Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 19
States / cities: Mesa, Arizona • Upland, California • Denver, Colorado + 15 more

Conditions: Healthy
Interventions: IVX-A12, Placebo; Biological
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more

Conditions: Adult Healthy Volunteers
Interventions: modified Handihaler DPI, standard Handihaler DPI; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: West Nile Fever
Interventions: ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 5
States / cities: Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more

Conditions: Healthy
Interventions: sertraline 100 mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Respiratory Tract Infection
Interventions: Formulation A, Formulation B, Formulation C, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more

Conditions: Cataract
Interventions: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Smoking Cessation
Interventions: NicVAX conjugate vaccine, Placebo; Biological
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Farmington, Connecticut + 6 more

Conditions: Gaucher Disease
Interventions: eliglustat; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Evansville, Indiana

Search by objective public record fields.

A Crisis Prevention Program for Youth With Autism

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

A Bioavailability Study of LY2452473 and Tadalafil

Study Comparing the Efficacy of Two Ibuprofen Formulations

ONC201 in Pediatric H3 K27M Gliomas

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

Abraxane and Alimta in Advanced Solid Tumors

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

Sun Protection Factor Assay

Sun Protection Factor Assay (SPF Assay 18677)

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

Efficacy of NicVAX in Smokers Who Want to Quit Smoking

Taste Evaluation of Different Liquid Formulations With Eliglustat